

Equioxx

57mg firocoxib

FIROCOXIB 57 MG CHEWABLE TABLETS FOR HORSES



The unique equine NSAID in tablet form



Long duration of action:
1 tablet per 24 hours



Equal clinical efficacy to phenylbutazone¹



Unique equine COX-2 selective NSAID



■ **Mode of action:** Firocoxib is a non-steroidal anti-inflammatory drug (NSAID) that acts by selective inhibition of cyclooxygenase-2 (COX-2) mediated prostaglandin synthesis. COX-2 is the isoform of the enzyme that has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. In in-vitro equine whole blood assays, firocoxib exhibited 222 to 643 fold selectivity for COX-2 over COX-1.

■ **Indications:** In horses: alleviation of pain and inflammation associated with osteoarthritis and reduction of associated lameness.

■ **Amounts to be administered and administration route:** Oral use. Administer one tablet once daily for horses weighing 450-600 kg bodyweight. Duration of treatment will be dependent on the response observed but should not exceed 14 days.

■ **Advice on correct administration:** One tablet should be administered with a small amount of food in a bucket or direct by hand, presenting the tablet combined with a small amount of food or with a treat in the palm of the hand. After administration, it is recommended to examine the buccal cavity to ensure that the tablet has been adequately swallowed.

■ **Contraindications:** do not use in animals suffering from gastrointestinal disorders and haemorrhage, impaired hepatic, cardiac or renal function and bleeding disorders. Do not use in breeding, pregnant or lactating animals. Do not use concomitantly with corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs). Do not use in case of hypersensitivity to the active substance or to any of the excipients.

■ **Adverse reactions:** lesions (erosion/ulceration) of the oral mucosa and of the skin around the mouth were very commonly observed in treated animals during tolerance studies. These lesions were mild and resolved without treatment. Salivation and labial and tongue oedema have been uncommonly associated with the oral lesions in a field study. The frequency of adverse reactions is defined using the following convention: very common (more than 1 in 10 animals treated displaying adverse reaction(s)), common (more than 1 but less than 10 animals in 100 animals treated), uncommon (more than 1 but less than 10 animals in 1,000 animals treated), rare (more than 1 but less than 10 animals in 10,000 animals treated), very rare (less than 1 animal in 10,000 animals, including isolated reports treated). If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

■ **Detection time:** 14 days.

■ **Withdrawal period:** Meat and offal: 26 days. Not authorized for use in animals producing milk for human consumption.

■ **Presentation:** • 1 cardboard box containing 60 tablets in a 30 ml bottle.
• 1 cardboard box containing 10 tablets in blisters.

■ **Dispensing classification of the drug:** POM-V.

Further information is available on request. Use medicines responsibly.

Composition

Firocoxib 57 mg

1. DOUCET M.Y., et al., Comparison of efficacy and safety of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis. JAVMA, Vol 232, 1, January 2008.